Literature DB >> 11815427

Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension.

Carmine Cardillo1, Umberto Campia, Crescence M Kilcoyne, Melissa B Bryant, Julio A Panza.   

Abstract

BACKGROUND: Hypertensive patients have both impaired endothelium-dependent vasodilation and increased activity of the endothelin (ET-1) system, which participate in their increased vascular tone and may predispose them to atherosclerosis. This study investigated the contribution of increased ET-1 activity to the impaired endothelium-dependent vasodilator function of hypertensive patients. METHODS AND
RESULTS: Forearm blood flow (FBF) responses to intraarterial infusion of acetylcholine (ACh; 7.5, 15, and 30 microg/min) and sodium nitroprusside (SNP; 0.8,1.6, and 3.2 microg/min) were assessed by strain-gauge plethysmography before and after nonselective blockade of ET(A) and ET(B) receptors by combined infusion of BQ-123 (ET(A) blocker; 100 nmol/min) and BQ-788 (ET(B) blocker; 50 nmol/min). During saline administration, the vasodilator response to ACh was significantly blunted in hypertensive patients compared with controls (P<0.001), whereas the vasodilator effect of SNP was not different between groups (P=0.74). Blockade of ET-1 receptors resulted in a significant increase in FBF from baseline in hypertensive patients (P<0.008) but not in controls (P=0.15). In hypertensive patients, a combined ET(A/B) blockade resulted in a significant potentiation of the vasodilator response to ACh compared with saline (P=0.01), whereas the response to SNP was unchanged (P=0.44). In contrast, the response to ACh was not significantly modified by ET-1 receptor antagonism in healthy subjects (P=0.14 compared with saline).
CONCLUSIONS: These findings indicate that blockade of ET-1 receptors improves endothelium-dependent vasodilator function in hypertensive patients, thereby suggesting that an increased ET-1 activity may play a role in the pathophysiology of this abnormality.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815427     DOI: 10.1161/hc0402.102989

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  22 in total

1.  Smooth Muscle Cell-Specific Disruption of the BBSome Causes Vascular Dysfunction.

Authors:  John J Reho; Deng-Fu Guo; Donald A Morgan; Kamal Rahmouni
Journal:  Hypertension       Date:  2019-08-19       Impact factor: 10.190

Review 2.  Is reversal of endothelial dysfunction still an attractive target in modern cardiology?

Authors:  Ify Mordi; Nikolaos Tzemos
Journal:  World J Cardiol       Date:  2014-08-26

3.  Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis.

Authors:  Martin Reriani; Eugenia Raichlin; Abhiram Prasad; Verghese Mathew; Geralyn M Pumper; Rebecca E Nelson; Ryan Lennon; Charanjit Rihal; Lilach O Lerman; Amir Lerman
Journal:  Circulation       Date:  2010-08-23       Impact factor: 29.690

4.  Vascular function and endothelin-1: tipping the balance between vasodilation and vasoconstriction.

Authors:  Steven K Nishiyama; Jia Zhao; D Walter Wray; Russell S Richardson
Journal:  J Appl Physiol (1985)       Date:  2016-12-01

Review 5.  Role of endothelin-1 in hypertension.

Authors:  Marc Iglarz; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

6.  Molecular and clinical aspects of endothelial dysfunction in diabetes.

Authors:  Carmela Nacci; Mariela Tarquinio; Monica Montagnani
Journal:  Intern Emerg Med       Date:  2009-03-10       Impact factor: 3.397

7.  Sex differences in endothelin-1-mediated vasoconstrictor tone in middle-aged and older adults.

Authors:  Brian L Stauffer; Christian M Westby; Jared J Greiner; Gary P Van Guilder; Christopher A Desouza
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-25       Impact factor: 3.619

Review 8.  Endothelin receptor antagonists in heart failure: current status and future directions.

Authors:  Georg Ertl; Johann Bauersachs
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Exercise and Aerobic Fitness to Reduce Cancer-Related Cardiovascular Toxicity.

Authors:  Umberto Campia; Ana Barac
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-07

Review 10.  Endothelin-1, aging and hypertension.

Authors:  Brian L Stauffer; Christian M Westby; Christopher A DeSouza
Journal:  Curr Opin Cardiol       Date:  2008-07       Impact factor: 2.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.